ARTICLE | Clinical News
Aptosyn exisulind: Phase III update
October 8, 2001 7:00 AM UTC
Cell Pathways Inc. (CLPA), Horsham, Penn. Product: Aptosyn exisulind Business: Cancer Therapeutic category: Apoptosis Target: cGMP-PDE Description: Oral sulfone metabolite of sulindac that augments ap...